CYANOBACTERIA AS A BIORESOURCE FOR PHARMACEUTICAL COMPOUNDS

New bioactive secondary metabolites are being produced by cyanobacteria, which is becoming a significant source. Recently, it has also been noted to be a plentiful source of bioactive compounds such lynbyabellin, curacin A, and apratoxins. Some substances have shown some extremely intriguing outcomes and successfully completed clinical studies in Phase II and Phase III. Additionally, cyanobacterial substances have a bright and promising future in scientific study and offer a big chance for the identification of novel drugs. 2005 saw the creation of new miniaturised screens based on cell cultures, enzyme activity, and ligand receptor binding thanks to a number of innovative technologies. This strategy has effects on the creation of new compounds for structure-based medication design. This review paper therefore primarily focuses on baseline data for encouraging the use of cyanobacterial bioactive chemicals as medications for many terrible human diseases, using the computational technique.